Africa Articles
Wednesday, July 8, 2026
PubNub Introduces Blocks.ai: The Control Plane and Network Layer For AI Agents
Landmark Global Galderma Survey Shows 9 out of 10 People Are Affected by Skin Quality Concerns
ZUG, Switzerland - Tuesday, 07. July 2026 AETOSWire Print
World’s most extensive skin quality profiling survey of more than 11,000 people across Europe, Asia, and the Americas finds that nine out of ten people are affected by skin quality concerns, with the most important attributes of good skin quality identified as smooth, hydrated and glowing skin1
Results show that skin quality has an impact on quality of life for 85% of people, with more than a third feeling self-conscious, insecure or anxious due to poor skin quality1
In response to clinicians’ calls for a universal assessment tool to help address these concerns, Galderma supported leading experts in the development of the Skin Quality Assessment Scale; a holistic, science-based tool to evaluate skin quality comprehensively and guide personalized, long-term treatment planning2
At Galderma, we champion skin quality by providing insights, tools, and solutions to better understand and address a wide spectrum of concerns, helping people take pride and feel comfortable in their own skin at every stage of life
(BUSINESS WIRE)--Galderma (SWX:GALD) has unveiled results from the world’s most extensive skin quality profiling survey, finding that skin quality concerns are widespread, can impact emotional wellbeing and, while differing based on the individual, are often similar among people alike in age, lifestyle, and environment.1 These results underscore the need for effective solutions that can be tailored to a wide variety of skin quality concerns.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706426842/en/
Key findings:1
Nine out of ten people globally are affected by skin quality concerns, with each person experiencing an average of two concerns in the past month
The most common concerns are fine lines and wrinkles (41%), dry skin (40%), and dull skin (37%), most frequently affecting the face
Skin quality impacts quality of life for 85% of people, with more than one in three reporting feelings of self-consciousness, insecurity or anxiety
Skin quality refers to how the skin looks, feels and functions on a day-to-day basis, including its hydration, elasticity, smoothness, radiance, firmness and tone.2 As we age and due to external factors, such as stress, diet, sun exposure, lack of sleep, pollution, or medication-driven weight loss, the amount and quality of the three main components of the skin – hyaluronic acid, elastin and collagen – decrease, leading to a deterioration in skin quality.1,3-6 This is often influenced by geography and culture, and can be accelerated at certain life stages, such as during the menopause, because of hormonal changes.3,4,6,7 Skin quality deterioration reflects visibly across the skin, through a rough or dry texture, an uneven skin tone, or a loss of radiance or firmness.2,3
To gain a detailed understanding of how people perceive skin quality and the concerns that matter most to them, Galderma conducted a survey of more than 11,000 people across 11 countries in four continents: Canada, the United States, Brazil, China, Korea, Thailand, India, France, Germany, Italy, and the United Kingdom. Results showed that skin quality concerns are highly prevalent and important, with nine out of ten people affected and each person experiencing an average of two concerns within the past month.1 The main concerns were fine lines and wrinkles, dry skin, and dull skin – experienced by 41%, 40% and 37% of people, respectively.1 Additionally, age spots, oily skin, decreased firmness and enlarged pores emerged as notable concerns.1 These were found to primarily affect the face, followed by the neck, legs and upper arms.1 Conversely, the most important attributes of good skin quality were smooth, hydrated and glowing skin.1
“Our skin evolves over time, influenced by both age and external factors. At Galderma, we don’t believe in one-size-fits-all solutions, we strive to be a trusted partner to people throughout their skin quality journey by offering comprehensive solutions to meet their diverse and evolving needs. This commitment begins with truly understanding these needs, which is why we conducted the world’s most extensive profiling survey to date.”
BILL ANDRIOPOULOS, PH.D.
HEAD OF GLOBAL MEDICAL AFFAIRS
GALDERMA
One in three people feel insecure or anxious due to skin quality concerns1
Skin quality affects more than appearance, influencing emotional wellbeing and shaping how comfortably and confidently people present themselves in their lives.2 Survey results showed that, for 85% of people, skin quality has an impact on their quality of life, with more than a third feeling self-conscious, insecure or anxious due to poor skin quality.1 All skin concerns were described as bothersome, with the most bothersome being scarring, including due to acne, followed by fine lines and wrinkles.1
This discomfort leads most people to either consider or actively seek ways to address skin quality concerns, in particular younger consumers.1 Approximately 70% of 18-34 year olds rated skin quality as eight out of ten in importance, with people most likely to take the first steps to improve the skin quality of their face at the age of 26.1 Respondents were most satisfied with hyaluronic acid injectables as treatments for the most common skin quality concerns of lines and wrinkles (86% very satisfied), dry skin (85%) and dull skin (82%).1
“What stood out from these survey insights was not just how common skin quality concerns are, but how they can differ based on age, lifestyle and environment. As clinicians, we see every day how challenging it can be to translate this complexity into meaningful, personalized care. That’s why I was proud to collaborate in the development of the Skin Quality Assessment Scale, an accessible, practical tool to help healthcare professionals and patients work together to create treatment plans that reflect their needs and how these evolve over time.”
DR. CHRISTOPH MARTSCHIN
DERMATOLOGIST
LISBON, PORTUGAL
Addressing patient concerns with the innovative Skin Quality Assessment Scale
To support the accurate assessment and treatment of skin quality concerns, Galderma brought together global dermatology experts to develop the Skin Quality Assessment Scale, the first holistic skin quality assessment tool of its kind.2 The scale helps identify treatment priorities, align expectations, support personalized long-term treatment planning, and track progress over time.2 It was created in response to a clear need identified by healthcare professionals: in a global clinician study, nearly two thirds reported not using any formal tool to assess skin quality, while 81% believed a simple, holistic assessment approach was missing in clinical practice.2 Following its development, 100% of participating clinicians agreed that the Skin Quality Assessment Scale supports a holistic understanding of skin quality, with 98% confirming that it helps guide treatment planning.2
With its decades of expertise in dermatology and aesthetics, and one of the broadest and most diverse portfolios, Galderma is uniquely positioned to address a range of skin quality concerns. Treatments such as Sculptra® and Restylane® Skinboosters™ work together to support skin quality by stimulating collagen and elastin production and enhancing hydration, respectively, helping to improve skin firmness, smoothness and overall radiance.8-17 Galderma designed the Glow on Holistic Individualized Treatment (HIT™) approach to support aesthetic practitioners in combining these two treatments to improve skin quality. Galderma’s Dermatological Skincare flagship brands, Alastin® and Cetaphil®, can also address a broad range of skin quality needs.18-24 The versatile Alastin range is made up of peri-procedural and daily skincare that supports the skin’s regeneration process to help restore a youthful appearance and enhance the visible outcomes of aesthetic and surgical procedures, whereas Cetaphil is designed for those with sensitive skin to help restore, protect and maintain the skin's health every day, building longevity and resilience over time.18-24
Read this report to find out more about how Galderma’s insights, tools, and solutions can support people at every step of their skin quality journey. More insights into the survey results can be found in this infographic.
About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
References
Galderma. Data on file. Skin Quality Consumer Survey.
Martschin C, et al. Development and validation of a novel holistic Skin Quality Assessment Scale. J Cosmet Dermatol. 2025;24(1):e16615. doi: 10.1111/jocd.16615.
Zhang S, Duan E. Fighting against Skin Aging. Cell Transplant. 2018;27(5):729-738. doi: 10.1177/0963689717725755.
Hussein RS, et al. Influences on skin and intrinsic aging: biological, environmental, and therapeutic insights. J Cosmet Dermatol. 2024;24(2):e16688. doi: 10.1111/jocd.16688.
Humphrey CD, Lawrence AC. Implications of Ozempic and other GLP-1 receptor agonists for facial plastic surgeons. Facial Plast Surg. 2023;39(6):719–721. doi: 10.1055/a-2148-6321.
Chylińska N and Maciejczyk M. Hyaluronic acid and skin: its role in aging and wound-healing processes, Gels. 2025;11(4):281. doi: 10.3390/gels11040281.
Reilly DM, Lozano J. Skin collagen through the lifestages: importance for skin health and beauty. Plast Aesthet Res. 2021;8:2. doi: 10.20517/2347-9264.2020.153.
Nikolis A, et al. A comprehensive interim analysis of skin hydration, barrier function (TEWL), elasticity, and patient satisfaction across two treatment arms. Interim Data on File. April 2026.
Waibel J, et al. A randomized, comparative study describing the gene signatures of poly-L-lactic acid (PLLA-SCA) and calcium hydroxylapaptite (CaHA) in the treatment of nasolabial folds. Poster presented at IMCAS World Congress; February 3-6, 2024; Paris, France.
Huth S, et al. Molecular insights into the effects of PLLA-SCA on gene expression and collagen synthesis in human 3d skin models containing macrophages. J Drugs Dermatol. 2024;23(4):285-288. doi: 10.36849/JDD.7791.
Sculptra®. EU Instructions for Use. 2025. Available online. Accessed June 2026.
Fabi S, et al. Effectiveness and safety of correction of cheek wrinkles using a biostimulatory poly-L-lactic acid injectable implant - clinical study data up to 24 months. Poster presented at IMCAS World Congress. January 26-28, 2023; Paris, France.
Bohnert K, et al. Randomized, controlled, multicentered, double-blind investigation of injectable poly-L-Lactic acid for improving skin quality. Plast Reconstr Surg. 2019;127(4):1684–1692. doi: 10.1097/DSS.0000000000001772.
Restylane® Skinboosters Vital Lidocaine™. IFU. August 2022. Available online. Accessed June 2026.
Restylane® Skinboosters Vital Light Lidocaine™. IFU. August 2021. Available online. Accessed June 2026.
Nikolis A, et al. Evaluating the role of small particle hyaluronic acid fillers using micro-droplet technique in the face, neck and hands: a retrospective chart review. Clin Cosmet Investig Dermatol. 2018;11:467–475. doi: 10.2147/CCID.S175408.
Streker M, et al. Stabilized hyaluronic acid-based gel of non-animal origin for skin rejuvenation: face, hand, and decolletage. J Drugs Dermatol. 2013;12(9):990–4. PMID: 24002145.
Gold M, et al. A multi-center clinical trial to evaluate the efficacy of the next generation TriHex Technology antiaging regimen. J Cosmet Dermatol. 2025;24(4):e70192. doi: 10.1111/jocd.70192.
Widgerow AD, et al. Extracellular matrix modulation: optimizing skin care and rejuvenation procedures. J Drugs Dermatol. 2016;15(Suppl 4):s63-s71. PMID: 27050707.
Widgerow AD, et al. Preoperative skin conditioning: extracellular matrix clearance and skin bed preparation, a new paradigm. Aesthet Surg J. 2019;39(Suppl_3):S103-S111. doi: 10.1093/asj/sjz022.
Galderma. Data on file. SPR.3540.207626.
Galderma. Data on file. SPR.3438.207553.
Galderma. Data on file. SPR.3438.207551.
Widgerow AD, et al. Novel strategy for strengthening dermatoporotic skin by managing cellular senescence. J Drugs Dermatol. 2024;23(9):748-756. doi: 10.36849/JDD.8388.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260706426842/en/
Permalink
https://www.aetoswire.com/en/news/54565300
Contacts
For further information:
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50
Richard Harbinson
Corporate Communications Director
richard.harbinson@galderma.com
+41 76 210 60 62
Céline Buguet
Franchises and R&D Communications Director
celine.buguet@galderma.com
+41 76 249 90 87
Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12
Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43
Andersen Global Adds Collaborating Firm Abcoo Law Firm
(BUSINESS WIRE) -- Andersen Global strengthens its presence in Türkiye with collaborating firm Abcoo Law Firm, enhancing the organization’s existing platform in the country with the addition of legal capabilities.
Founded in 2014, Abcoo advises local and international clients across a broad range of legal services, with experience in corporate and M&A, real estate and construction, dispute resolution, employment, compliance, banking and finance, competition and intellectual property law. The firm is consistently recognized as a top tier and leading firm by international publications, including The Legal 500. Abcoo supports organizations across a wide range of industries, including real estate and construction, retail, textile, cosmetics, automotive, logistics, chemicals, IT, energy, healthcare, manufacturing and financial services, providing strategic legal guidance and commercially focused solutions.
“Our focus has always been on understanding each client’s objectives and providing practical, commercially driven legal solutions that support long-term success,” said the senior partners of Abcoo. “Collaborating with Andersen Global allows us to further strengthen our international reach while continuing to deliver responsive, solution-oriented service in increasingly complex legal and regulatory environments.”
“Abcoo brings substantial experience across a wide range of legal and commercial matters that are increasingly important to businesses operating internationally,” said Mark L. Vorsatz, global chairman and CEO of Andersen. “Their addition enhances our ability to support clients throughout the country and the broader region with coordinated legal services grounded in deep local knowledge.”
Andersen Global is an international association of legally separate, independent member firms comprised of tax, legal, and valuation professionals around the world. Established in 2013 by U.S. member firm Andersen Tax LLC, Andersen Global now has more than 50,000 professionals worldwide and a presence in over 1,000 locations through its member firms and collaborating firms.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260707286032/en/
Permalink
https://www.aetoswire.com/en/news/0707202656088
Contacts
Megan Tsuei
Andersen Global
415-764-2700
Modon's Hudayriyat Golf Estates sets UAE record with more than AED 13 billion in sales within days of launch
A record-breaking sales value for a residential project in the UAE
The project comprises golf mansions, villas, and townhouses across Hudayriyat Island, Abu Dhabi
1,700 residences sold within days after the launch
15% non-UAE resident buyers
81% new customers to Modon
Modon has set a new benchmark for the UAE real estate market with the launch of Hudayriyat Golf Estates on Hudayriyat Island, Abu Dhabi.
Within days of launch, the community achieved record-breaking sales exceeding AED 13 billion, marking the highest publicly recorded sales value for a single residential project launch in the UAE.
Comprising an exclusive collection of golf mansions, villas, and townhouses, the development saw 1,700 of its residences sold after few days of launch.
The response from buyers and investors reflects confidence in Abu Dhabi’s real estate market and Modon’s development vision, while reinforcing Hudayriyat Island’s position as a premier lifestyle destination.
Designed around privacy, wellbeing and premium living, the gated community attracted strong interest, with 15% being non-UAE resident, and 81% being new customers to Modon. Andalusian-inspired architecture, dual waterfront and fairway views, and a 95-hectare golf course are integrated within a walkable masterplan. A 2.3-kilometre green spine connects a range of amenities, including a clubhouse, wellness and fitness facilities, retail and leisure offerings, co-working spaces and a school.
His Excellency Jassem Mohamed Bu Ataba Al Zaabi, Chairman of Modon Holding, said: “This strong demand reflects the growing global confidence in Abu Dhabi and the UAE, underpinned by the leadership’s long-term vision, economic strength and commitment to sustainable development. It reinforces the emirate’s position as one of the world’s most attractive destinations for investment, talent and quality of life.”
Bill O’Regan, Group Chief Executive Officer of Modon Holding, said: “This response reflects a broader shift in how people choose where to live. Buyers increasingly seek communities that combine quality homes with lifestyle, wellbeing and connectivity. At Modon, our focus is on creating integrated destinations that bring these elements together in a way that delivers enduring value for residents, investors and the wider city.”
Ibrahim Al Maghribi, Chief Executive Officer of Modon Real Estate, added: “Hudayriyat Golf Estates has been designed to offer a distinctive residential experience centred around quality, privacy and active living. The response from buyers reflects the appeal of the community, its unique setting and the strength of demand for thoughtfully planned homes in Abu Dhabi. We are grateful for the trust placed in Modon and look forward to bringing this community to life.”
Located approximately 20 minutes from downtown Abu Dhabi and 30 minutes from Zayed International Airport, Hudayriyat Golf Estates also provides direct access to Hudayriyat Island’s sports and leisure attractions, including Surf Abu Dhabi, the Velodrome and an extensive network of cycling, running and recreational trails.
For more information and to register interest in future developments, prospective investors can visit www.modon.com or call 800 MODON.
About Modon:
Modon is an international holding company, headquartered in Abu Dhabi, United Arab Emirates, and listed on the Abu Dhabi Securities Exchange (ADX). Modon is at the forefront of urban innovation, creating iconic designs and experiences that continually surpass expectations. From real estate to hospitality, asset and investment management, events, catering and tourism, and urban infrastructure, we are bringing cities to life through delivering long-term and sustainable value.
Modon’s social media accounts:
X
YouTube
Permalink
https://www.aetoswire.com/en/news/mdn772026e
Contacts
press@modon.com
ir@modon.com
www.modon.com
Ahmed Abu Shehab
Public Relations and Communications, Modon
Ahmed.abushehab@modon.com
Rawad Khattar
Weber Shandwick
rkhattar@webershandwick.com
Loomis Sayles Growth Equity Strategies Team Celebrates Twenty-Year Milestones
BOSTON - Tuesday, 07. July 2026 AETOSWire
(BUSINESS WIRE) -- Loomis, Sayles & Company, the century-old investment manager with nearly $418 billion in assets under management, proudly celebrates the 20-year anniversaries of the Loomis Sayles Large Cap Growth and the Loomis Sayles All Cap Growth strategies, as well as a differentiated approach to growth equity investing under the leadership of Aziz V. Hamzaogullari, CFA, the founder, chief investment officer and portfolio manager of the Loomis Sayles Growth Equity Strategies (GES) Team. Aziz is also an executive vice president and a member of the firm’s Board of Directors.
Celebrating 20 Years of The Power of Active Management Done Right
GES is a cohesive team with 20 years of alpha generation and a long-term, private equity approach to investing.
Under Aziz Hamzaogullari’s leadership since 2010, assets under management for GES have grown from $1.9 billion to $98.2 billion as of 31 May 2026.
Aziz brought a differentiated approach to equity investing when he joined Loomis Sayles in 2010. A proprietary seven-step research framework (QGV7+) supports the GES Team’s long-term, private equity approach to investing. The Team seeks to invest in those few high-quality businesses with sustainable competitive advantages and profitable growth only when they trade at a discount to the GES estimate of intrinsic value.
Underpinned by this singular investment philosophy, the GES Team expanded its platform from US-focused Large Cap Growth and All Cap Growth strategies to also include Global Growth and International Growth long-only strategies as well as a Long/Short Growth Equity hedge fund strategy. These strategies are available in the US through vehicles including mutual funds, managed accounts, CITs and an ETF as well as UCITS and other vehicles outside the US.
The GES Team believes a focus on the quality of a manager’s investment philosophy, process and decision-making is essential for assessing the probability of future success. The GES alpha thesis encapsulates a deeply held system of persistent beliefs, a rigorous, repeatable investment process and substantive proof points.
“Since joining Loomis Sayles in 2010, Aziz and the Growth Equity Strategies (GES) Team have exemplified excellence through their unwavering commitment to delivering superior risk-adjusted returns for our clients,” said Kevin Charleston, Chief Executive Officer, Loomis Sayles. “Their distinctive investment philosophy, grounded in a disciplined and differentiated approach, has consistently driven strong performance. We are immensely proud of the GES Team’s achievements and the lasting impact they continue to make.”
“I want to sincerely thank our investors for their continued trust and confidence. We remain firmly committed to our core principles of long-term investing, guided by the differentiated insights that define our approach,” said Aziz V. Hamzaogullari, CFA, Founder, Chief Investment Officer and Portfolio Manager, Loomis Sayles Growth Equity Strategies Team.
Learn More About the Loomis Sayles Growth Equity Strategies Team
ABOUT LOOMIS SAYLES
For a century, Loomis, Sayles & Company has built a legacy focused on fulfilling the investment needs of institutional and retail clients worldwide. To do this, our performance-driven investors aim to deliver long-term results by leveraging deep, independent research and rigorous risk analysis. With the resources, foresight, and flexibility to look far and wide for value in broad and narrow markets, Loomis Sayles has remained a trusted partner to its clients since 1926. Loomis Sayles proudly manages $417.9 billion* in assets on behalf of clients worldwide (as of March 31, 2026).
*Includes the assets of both Loomis, Sayles & Co., LP, and Loomis Sayles Trust Company, LLC. ($53.9 billion for the Loomis Sayles Trust Company). Loomis Sayles Trust Company is a wholly owned subsidiary of Loomis, Sayles & Company, L.P.
8998021.1.1
View source version on businesswire.com: https://www.businesswire.com/news/home/20260707992418/en/
Permalink
https://www.aetoswire.com/en/news/0707202656089
Contacts
Kate Sheehan
+1 617 960-4447
ksheehan@loomissayles.com
SS&C Expands Tokenized Investment Capabilities with Digital Cash Settlement
WINDSOR, Conn. -
Building on live tokenized fund issuance and distribution capabilities, SS&C extends its innovation roadmap to support the next stage of digital investment markets
(BUSINESS WIRE) -- SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced plans to enable digital cash settlement for tokenized investment transactions using regulated forms of digital cash, including stablecoins and tokenized commercial bank deposits.
The announcement builds on the successful launch of SS&C's live tokenized fund issuance and distribution capabilities earlier this year following the acquisition of Calastone in 2025. SS&C already enables asset managers to bring tokenized versions of traditional investment funds to market through the infrastructure and connectivity they already use, helping bridge traditional and digital investment markets.
As interest in tokenized investment products continues to grow, the market is increasingly looking beyond tokenization towards the infrastructure needed to support digital transactions. Having already enabled the issuance and distribution of tokenized funds, SS&C is now extending its innovation roadmap to support the next stage of the digital investment lifecycle.
The planned capabilities will enable digital investment transactions to settle using regulated forms of digital cash, including stablecoins and tokenized commercial bank deposits. Designed to support future atomic settlement, they will help reduce settlement risk, improve operational efficiency and simplify cross-border investment transactions as digital markets continue to evolve.
Together with SS&C's existing tokenized fund issuance and distribution capabilities, these planned enhancements create a pathway for eligible funds across the combined SS&C and Calastone ecosystem to be transacted and settled using digital forms of cash. The capability further extends the practical application of tokenized investment products.
“Tokenized funds are becoming another mainstream investment structure alongside mutual funds and ETFs. As asset managers begin supporting these products in production, they need infrastructure that evolves with them,” said Nick Wright, General Manager, SS&C Global Investor & Distribution Solutions. “Today's announcement represents another step in helping clients make that transition, building on our live tokenized fund issuance and distribution capabilities with the digital cash settlement infrastructure needed to support the next stage of market adoption. Following the acquisition of Calastone, we have continued to invest in expanding these capabilities, helping clients adopt digital investments with confidence while leveraging the scale, resilience and connectivity they already rely on.”
The planned enhancements reinforce SS&C's continued investment in digital innovation following the acquisition of Calastone and demonstrate the company's commitment to delivering practical capabilities to help clients prepare for the future of investment management.
Further details regarding product availability and implementation timelines will be announced as development milestones are achieved.
Forward-looking statements
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, forward-looking statements can be identified by the use of forward-looking terms such as “anticipate,” “estimate,” “believe,” “continue,” “could,” “intend,” “may,” “plan,” “potential,” “predict,” “should,” “will,” “expect,” “objective,” “projection,” “forecast,” “goal,” “guidance,” “outlook,” “effort,” “target,” “trajectory” or the negative of these terms or other comparable terms. These forward-looking statements are based on certain assumptions and analyses made by us in light of our experience and our perception of historical trends, current conditions and expected future developments, as well as other factors we believe are appropriate in the circumstances. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are subject to and qualified by these cautionary statements and also by the risks described in the company’s securities filings with the U.S. Securities and Exchange Commission, and there can be no assurance that the actual results or developments anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Forward-looking statements speak only as of the date of this release and the Company undertakes no obligation to update or revise them, whether as a result of new information, future events, or otherwise, except as required by law.
About SS&C Technologies
SS&C is a leading provider of mission-critical, AI-powered software and services empowering financial services and healthcare organizations to work smarter, faster, and securely. Founded in 1986, SS&C is headquartered in Windsor, Connecticut, and has offices worldwide. More than 23,000 financial services and healthcare organizations, from the world's largest companies to small and mid-market firms, rely on SS&C for expertise, scale and technology. Additional information about SS&C (Nasdaq: SSNC) is available at www.ssctech.com.
Follow SS&C on X, LinkedIn and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260707147677/en/
Permalink
https://www.aetoswire.com/en/news/0707202656086
Contacts
For more information
Brian Schell | Chief Financial Officer, SS&C Technologies
Tel: +1-816-642-0915| E-mail: InvestorRelations@sscinc.com
Justine Stone | Investor Relations, SS&C Technologies
Tel: +1-212-367-4705 | E-mail: InvestorRelations@sscinc.com
Media Contacts
Breanna King
Prosek Partners
Email : pro-SSC@prosek.com
Morinaga Milk Achieves Self-Affirmed GRAS Status for LAC-Living+™, Expanding U.S. Opportunities for Its Postbiotic Ingredient
TOKYO - Tuesday, 07. July 2026
Clinical evidence–backed postbiotic supports mood and well-being with formulation flexibility for diverse applications
(BUSINESS WIRE)--Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy and functional ingredient company, today announced that it has achieved self-affirmed GRAS (Generally Recognized As Safe) status in the United States for LAC-Living+™ (L. helveticus MCC1848), its proprietary postbiotic ingredient. This milestone expands the commercial availability of LAC-Living+ in the U.S. market and enables its use in dietary supplements, functional foods, and beverages, supporting the development of products designed to address growing consumer demand for health and well-being solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706806943/en/
Growing Interest in Postbiotics and Mental Well-Being
Consumer interest in proactive health management has expanded significantly in recent years, alongside increasing awareness of the connection between the gut and the brain, commonly referred to as the gut–brain axis. As a result, the global functional ingredient market is evolving beyond conventional probiotics to include postbiotics—non-viable microorganisms and/or their components that offer physiological benefits. Postbiotics are gaining attention due to their stability, safety, and ease of formulation, particularly in product formats that are challenging for live microorganisms. These advantages make them an attractive option for manufacturers seeking reliable, science-based ingredients.
Morinaga Milk has been at the forefront of postbiotic research and development. In 2018, the company achieved self-affirmed GRAS status for LAC-Shield™ (L. paracasei MCC1849), its first postbiotic ingredient. Building on this experience, LAC-Living+™ represents the company’s second postbiotic innovation, developed to address emerging consumer needs in the area of mood and mental well-being.
LAC-Living+™: Clinical Evidence Supporting Everyday Well-Being
LAC-Living+™ (L. helveticus MCC1848) is a heat-treated postbiotic ingredient developed to combine scientific credibility with formulation flexibility. Its functionality has been evaluated in human clinical studies, which suggest that supplementation with LAC-Living+ may help support mental well-being and quality of life, particularly in individuals experiencing everyday stress. Reported outcomes have included improvements in indicators related to mood and psychological state, providing a scientific basis for its application in products targeting mental wellness. In Japan, L. helveticus MCC1848 has also been accepted as a functional ingredient under the Foods with Function Claims (FFC) system, with reported functionality to help maintain a positive mood (vitality) in situations involving temporary mental stress. While research into the gut–brain axis continues to evolve, such findings and achievements are contributing to a growing body of evidence supporting the role of microbiome-related ingredients in holistic health approaches that integrate physical and mental well-being.
Formulation Advantages for Broad Applications
In addition to its scientific foundation, LAC-Living+™ offers important technical advantages for product development.
As a postbiotic ingredient, LAC-Living+™ is non-viable, which allows it to maintain stability under conditions that may compromise live microorganisms. This includes exposure to heat processing, moisture, and extended shelf-life environments, making it suitable for a wide variety of applications. These characteristics provide manufacturers with greater flexibility in formulation and product design, supporting its use across categories such as ready-to-drink beverages, powders, bars, gummies, dairy products, and supplements.
Supporting Innovation in the U.S. Market
The attainment of self-affirmed GRAS status represents a key step in enabling broader adoption of LAC-Living+™ in the United States.
“Achieving self-affirmed GRAS status for LAC-Living+™ marks an important milestone for our postbiotic portfolio,” said Masashi Kamiya, General Manager of Functional Food Ingredients Division at Morinaga Milk Industry Co., Ltd. “With increasing interest in mental well-being and convenient health solutions, we believe LAC-Living+™ offers strong potential to support our partners in developing innovative products tailored to evolving consumer needs.”
Morinaga Milk remains committed to advancing its research and ingredient development efforts, with a focus on delivering safe, scientifically supported, and application-friendly solutions to the global market.
About Morinaga Milk Industry Co., Ltd.
Morinaga Milk Industry Co., Ltd. is one of Japan’s leading dairy companies, with more than 100 years of experience in harnessing the nutritional value of dairy and functional ingredients.
The company is recognized globally for its expertise in probiotics, postbiotics, and microbiome-related research, supported by decades of scientific investigation into the safety, functionality, and mechanisms of action of beneficial microorganisms. Since the 1960s, Morinaga Milk has been advancing research into bifidobacteria and their role in human health, contributing to the development of high-quality, science-based solutions for a wide range of applications.
For more information about Morinaga probiotics and postbiotics, please visit: https://morinagamilk-ingredients.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20260706806943/en/
Permalink
https://www.aetoswire.com/en/news/54565568
Contacts
Morinaga Milk Industry Co., Ltd.
Investor& Public Relations Department: Kazuaki Kajikawa
Functional Food Ingredients Division: Saki Yamashita
E-mail:interntl-pr@morinagamilk.co.jp
Morinaga Milk website: https://www.morinagamilk.co.jp/english/